

**Table S2: Clinical and procedural characteristics of male patients with and without concomitant atrial fibrillation before and after propensity score matching.** Data presented as percentages or mean  $\pm$  SD. \* - Data presented as median with interquartile range (IQR). # - MR grade according to American Society of Echocardiography (ASE) classification. AF – atrial fibrillation. COPD – chronic obstructive pulmonary disease. CABG – coronary artery bypass graft surgery. PCI – percutaneous coronary intervention. ICD – implantable cardioverter defibrillator. CRT – cardiac resynchronization therapy. GFR – glomerular filtration rate. LV function – left ventricular function. LA – left atrial. NT-proBNP – N-terminal pro-B-type natriuretic peptide. TR – tricuspid regurgitation. MR – mitral regurgitation. MACCE – major adverse cardiac and cerebrovascular events. AAD – antiarrhythmic drugs. ACE – angiotensin converting enzyme. AT1 – angiotensin II type 1 receptor. ARN – angiotensin receptor neprylisin. SGLT-II – sodium-glucose transporter 2.

Variable	Before Propensity Score Matching				After Propensity Score Matching		
	Overall (n=514)	No AF (n=123)	AF (n=391)	p-value	No AF (n=123)	AF (n=246)	p-value
Age (years)	77.0 $\pm$ 8.5	75.0 $\pm$ 9	77.6 $\pm$ 8.3	<b>0.01</b>	75.0 $\pm$ 9	76.0 $\pm$ 8	0.3
euroSCORE II*	16.5 (20.2)	16.7 (18.5)	16.5 (21.4)	0.7	16.7 (18.5)	18.3 (21.9)	0.3
STS Risk Score*	7 (8.6)	6.9 (8.8)	7 (8.5)	0.4	6.9 (8.8)	7 (8.7)	0.4
NYHA class I	0% (0)	0% (0)	0% (0)	0.6	0% (0)	0% (0)	0.3
NYHA class II	3.3% (17)	2.4% (3)	3.6% (14)		2.4% (3)	2.4% (6)	
NYHA class III	74.9% (385)	78.9% (97)	73.7% (288)		78.9% (97)	71.5% (176)	
NYHA class IV	21.8% (112)	18.7% (23)	22.8% (89)		18.7% (23)	26% (64)	
COPD	19.3% (99)	21.1% (26)	18.7% (73)	0.6	21.1% (26)	21.5% (53)	1
CAD	67.7% (348)	73.2% (90)	66% (258)	0.2	73.2% (90)	74% (182)	0.9
Prior CAB-OP	33.5% (172)	42.3% (52)	30.7% (120)	<b>0.02</b>	42.3% (52)	34.1% (84)	0.1
Prior PCI	56% (288)	58.5% (72)	55.2% (216)	0.5	58.5% (72)	58.1% (143)	1
Pre-existing ICD	30% (154)	29.3% (36)	30.2% (118)	0.9	29.3% (36)	35.8% (88)	0.2

Pre-existing CRT	18.7% (96)	18.7% (23)	18.7% (73)	1	18.7% (23)	21.1% (52)	0.7
Diabetes mellitus	30.5% (157)	31.7% (39)	30.2% (118)	0.7	31.7% (39)	32.1% (79)	1
Arterial hypertension	82.1% (422)	81.3% (100)	82.4% (322)	0.8	81.3% (100)	81.7% (201)	1
Prior Stroke	9.7% (50)	6.5% (8)	10.7% (42)	0.2	6.5% (8)	10.6% (26)	0.3
LVEF ≥50%	32.5% (167)	25.2% (31)	34.8% (136)	0.08	25.2% (31)	27.6% (68)	0.7
LVEF 41-49%	10.5% (54)	8.9% (11)	11% (43)		8.9% (11)	11% (27)	
LVEF ≤40%	57% (293)	65.9% (81)	54.2% (212)		65.9% (81)	61.4% (151)	
GFR (mL/Min)	51 ± 28	54 ± 26	51 ± 28	0.3	54 ± 26	54 ± 21	0.3
NT-proBNP (ng/L)*	2463 (5288)	2069 (6005)	2473 (5049)	0.6	2069 (6005)	2466 (5232)	0.7
TR grade III	17.9% (92)	11.4% (14)	19.9% (78)	<b>0.03</b>	11.4% (14)	10.2% (25)	0.7
Degenerative MR etiology	33.9% (174)	35.8% (44)	33.2% (130)	0.2	35.8% (44)	30.9% (76)	0.6
Functional MR etiology	55.4% (285)	57.7% (71)	54.7% (214)		57.7% (71)	60.6% (149)	
Mixed MR etiology	10.7% (55)	6.5% (8)	12% (47)		6.5% (8)	8.5% (21)	
Median procedure duration (min)*	83 (63)	85 (62)	83 (63)	0.9	85 (62)	82 (63)	0.9
Number of clips implanted*	2 (1)	2 (1)	2 (1)	1	2 (1)	2 (1)	0.8
Periprocedural MR reduction <sup>#</sup>	Δ2.1 ± 0.6	Δ2.0 ± 0.6	Δ2.1 ± 0.6	0.3	Δ2.0 ± 0.6	Δ2.1 ± 0.6	0.4
Length of hospital stay (days)*	6 (5)	6 (5)	6 (5)	0.6	6 (5)	6 (5)	0.9
Overall-MACCE	5.6% (29)	6.5% (8)	5.4% (21)	0.7	6.5% (8)	5.7% (14)	0.8
<i>Cerebral/systemic thromboembolic event</i>	<i>0.8% (4)</i>	<i>0.8% (1)</i>	<i>0.8% (3)</i>	<i>1</i>	<i>0.8% (1)</i>	<i>0.8% (1)</i>	<i>1</i>

<i>Bleeding requiring intervention</i>	3.1% (16)	3.3% (4)	3.1% (12)	1	3.3% (4)	3.3% (8)	1
<i>In-hospital death from cardiovasc. cause</i>	2.3% (12)	2.4% (3)	2.3% (9)	1	2.4% (3)	2.4% (6)	1
In-hospital death from any cause	4% (21)	4.9% (6)	3.8% (15)	0.6	4.9% (6)	4.5% (11)	1
<b>Heart Failure Therapy</b>							
ACE-/AT1 Inhibitors	69.6% (358)	66.7% (82)	70.6% (276)	0.4	66.7% (82)	67.1% (165)	1
ARN Inhibitor	16.7% (86)	17.1% (21)	16.6% (65)	0.9	17.1% (21)	19.9% (49)	0.6
Beta Blockers	88.1% (453)	87.8% (108)	88.2% (345)	0.9	87.8% (108)	88.6% (218)	0.9
Loop diuretics	89.7% (461)	86.2% (106)	90.8% (355)	0.2	86.2% (106)	89% (219)	0.5
Thiazid diuretics	18.7% (96)	18.7% (23)	18.7% (73)	1	18.7% (23)	18.3% (45)	1
Aldosteron antagonists	50.2% (258)	50.4% (62)	50.1% (196)	1	50.4% (62)	49.6% (122)	0.9
Ivabradin	1.6% (8)	4.1% (5)	0.8% (3)	<b>0.02</b>	4.1% (5)	1.2% (3)	0.1
Digitalis	7.4% (38)	0.8% (1)	9.5% (37)	<b>&lt;0.001</b>	0.8% (1)	8.5% (21)	<b>0.002</b>
SGLT-II-Inhibitors	6% (31)	8.1% (10)	5.4% (21)	0.3	8.1% (10)	4.1% (10)	0.1
Vericiguat	0.2% (1)	0% (0)	0.3% (1)	1	0% (0)	0.4% (1)	1